RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000075.xml
Semin Respir Crit Care Med 2002; 23(2): 177-188
DOI: 10.1055/s-2002-25306
DOI: 10.1055/s-2002-25306
Genetics of Pulmonary Fibrosis
Mark M. Wurfel, Ganesh Raghu- Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
24. April 2002 (online)
ABSTRACT
Pulmonary fibrosis is a devastating disease that occurs in association with environmental exposures, several inherited diseases, collagen vascular disease, as well as in an idiopathic form. Epithelial cell damage, excessive fibroblast proliferation, upregulation of extracellular matrix production, and attenuated matrix degradation are shared pathophysiological features of these different forms of pulmonary fibrosis. Several observations suggest that genetic predisposition plays an important role in the pathophysiology of pulmonary fibrosis. There is significant inter-individual variation in the degree of pulmonary fibrosis resulting from exposure to similar levels of an inhaled fibrogenic agent. There are several inherited diseases with known genetic mutations that have high rates of pulmonary fibrosis. Idiopathic pulmonary fibrosis can occur in multiple first-degree relatives, including those separated at an early age. Finally, recent studies have identified polymorphisms within genes for cytokines, histocompatability antigens, and extracellular matrix components that are associated with the development of pulmonary fibrosis. Identification of putative pulmonary fibrosis gene/s (PF gene/s) may result in novel diagnostic and therapeutic interventions for those at risk for development of pulmonary fibrosis.
KEYWORD
Pulmonary fibrosis - usual interstitial pneumonitis - genetic predisposition - inherited disorders - fibroproliferation
REFERENCES
- 1 Selman M, King T E, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med . 2001; 134 136-151
- 2 Wagner G R. Asbestosis and silicosis. Lancet . 1997; 349 1311-1315
- 3 NIOSH. NIOSH Alert: Request for Assistance in Preventing Silicosis and Deaths from Sandblasting. Cincinnati, Ohio: DHHS National Institute for Occupational Safety and Health 1996: 92-102
- 4 Landrigan P. Silicosis. Occup Med State Art Rev . 1987; 2 319-326
- 5 Mossman B T, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med . 1998; 157 1666-1680
- 6 Nagelschmidt G. The relation between lung dust and lung pathology in pneumoconiosis. Br J Ind Med . 1960; 17 247-259
- 7 Piguet P F, Collart M A, Grau G E. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature . 1990; 344 245-247
- 8 Davis G S, Pfeiffer L M, Hemenway D R. Persistent overexpression of interleukin-1beta and tumor necrosis factor-alpha in murine silicosis. J Environ Pathol Toxicol Oncol . 1998; 17 99-114
- 9 Piguet P F, Vesin C, Grau G E. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine . 1993; 5 57-61
- 10 Mariani T J, Roby J D, Mecham R P. Localization of type I procollagen gene expression in silica-induced granulomatous lung disease and implication of transforming growth factor-beta as a mediator of fibrosis. Am J Pathol . 1996; 148 151-164
- 11 Yucesoy B, Vallyathan V, Landsittel D P. Polymorphisms of the IL-1 gene complex in coal miners with silicosis. Am J Ind Med . 2001; 39 286-291
- 12 Yucesoy B, Vallyathan V, Landsittel D P. Association of tumor necrosis factor-alpha and interleukin-1 gene polymorphisms with silicosis. Toxicol Appl Pharmacol . 2001; 172 75-82
- 13 Kreiss K, Danilovs J A, Newman L S. Histocompatibility antigens in a population based silicosis series. Br J Ind Med . 1989; 46 364-369
- 14 Honda K, Kimura A, Dong R P. Immunogenetic analysis of silicosis in Japan. Am J Respir Cell Mol Biol . 1993; 8 106-111
- 15 Brodkin C A, Barnhart S, Anderson G. Correlation between respiratory symptoms and pulmonary function in asbestos-exposed workers. Am Rev Respir Dis . 1993; 148 32-37
- 16 ATS. American Thoracic Society. Medical Section of the American Lung Association: the diagnosis of nonmalignant diseases related to asbestos. Am Rev Respir Dis . 1986; 134 363-368
- 17 Staples C A. Computed tomography in the evaluation of benign asbestos-related disorders. Radiol Clin North Am . 1992; 30 1191-1207
- 18 Craighead J E, Abraham J L, Churg A. The pathology of asbestos-associated diseases of the lungs and pleural cavities: diagnostic criteria and proposed grading schema. Report of the Pneumoconiosis Committee of the College of American Pathologists and the National Institute for Occupational Safety and Health. Arch Pathol Lab Med . 1982; 106 544-596
- 19 Browne K. Asbestos-related disorders. In: Parkes WR, ed. Occupational Lung Disorders 3rd ed. Oxford: Butterworth-Heinemann 1994: 411-504
- 20 Merchant J A, Klouda P T, Soutar C A. The HL-A system in asbestos workers. Br Med J . 1975; 1 189-191
- 21 Matej H, Lange A, Smolik R. HLA antigens in asbestosis. Arch Immunol Ther Exp (Warsz) . 1977; 25 489-491
- 22 Gregor A, Singh S, Turner-Warwick M. The role of histocompatibility (HLA) antigens in asbestosis. Br J Dis Chest . 1979; 73 245-252
- 23 Turner-Warwick M. HLA phenotypes in asbestos workers. Br J Dis Chest . 1979; 73 243-244
- 24 Begin R, Menard H, Decarie F. Immunogenetic factors as determinants of asbestosis. Lung . 1987; 165 159-163
- 25 Darke C, Wagner M M, McMillan G H. HLA-A and B antigen frequencies in an asbestos exposed population with normal and abnormal chest radiographs. Tissue Antigens . 1979; 13 228-232
- 26 Evans C C, Lewinsohn H C, Evans J M. Frequency of HLA antigen in asbestos workers with and without pulmonary fibrosis. Br Med J . 1977; 1 603-605
- 27 Shih J F, Hunninghake G W, Goeken N E. The relationship between HLA-A, B, DQ, and DR antigens and asbestos-induced lung disease. Chest . 1993; 104 26-31
- 28 Zhang Y, Lee T C, Guillemin B. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol . 1993; 150 4188-4196
- 29 Bissonnette E, Rola-Pleszczynski M. Pulmonary inflammation and fibrosis in a murine model of asbestosis and silicosis: possible role of tumor necrosis factor. Inflammation . 1989; 13 329-339
- 30 Briggs D C, Vaughan R W, Welsh K I. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet . 1991; 338 661-662
- 31 King T E. Connective tissue disease. In: Schwarz MI, King TE, eds. Interstitial lung disease St. Louis: Mosby-Year Book 1993: 271-308
- 32 Valentini G. Classification of systemic sclerosis. Clin Dermatol . 1994; 12 217-223
- 33 Mitchell H, Bolster M B, LeRoy E C. Scleroderma and related conditions. Med Clin North Am . 1997; 81 129-149
- 34 D'Angelo W A, Fries J F, Masi A T. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med . 1969; 46 428-440
- 35 Warrick J H, Bhalla M, Schabel S I. High resolution computed tomography in early scleroderma lung disease. J Rheumatol . 1991; 18 1520-1528
- 36 Silver R M, Warrick J H, Kinsella M B. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol . 1993; 20 838-844
- 37 Akesson A, Scheja A, Lundin A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum . 1994; 37 729-735
- 38 Lynch C J, Singh G, Whiteside T L. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma). J Clin Immunol . 1982; 2 314-318
- 39 Bianchi D W, Zickwolf G K, Weil G J. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A . 1996; 93 705-708
- 40 Nelson J L, Furst D E, Maloney S. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet . 1998; 351 559-562
- 41 Maloney S, Smith A, Furst D E. Microchimerism of maternal origin persists into adult life. J Clin Invest . 1999; 104 41-47
- 42 Avila J J, Lympany P A, Pantelidis P. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol . 1999; 20 106-112
- 43 Limper A H, Roman J. Fibronectin: a versatile matrix protein with roles in thoracic development, repair and infection. Chest . 1992; 101 1663-1673
- 44 Bitterman P, Rennard S, Adelberg S. Role of fibronectin in fibrotic lung disease: a growth factor for human lung fibroblasts. Chest . 1983; 83 96S
- 45 ATS. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med . 2000; 161 646-664
- 46 Ortiz L A, Lasky J, Lungarella G. Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol . 1999; 20 825-833
- 47 Munger J S, Huang X, Kawakatsu H. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell . 1999; 96 319-328
- 48 Ziegenhagen M W, Schrum S, Zissel G. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med . 1998; 46 223-231
- 49 Coker R K, Laurent G J, Jeffery P K. Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax . 2001; 56 549-556
- 50 Peabody J W. Idiopathic pulmonary fibrosis: its occurance in identical twin sisters. Dis Chest . 1950; 18 330-334
- 51 Javaheri S, Lederer D H, Pella J A. Idiopathic pulmonary fibrosis in monozygotic twins: the importance of genetic predisposition. Chest . 1980; 78 591-594
- 52 Swaye P, Van Ordstrand S H, McCormack L J. Familial Hamman-Rich syndrome: report of eight cases. Dis Chest . 1969; 55 7-12
- 53 Turton C W, Morris L M, Lawler S D. HLA in cryptogenic fibrosing alveolitis. Lancet . 1978; 1 507-508
- 54 Evans C C. HLA antigens in diffuse fibrosing alveolitis. Thorax . 1976; 31 483
- 55 Libby D M, Gibofsky A, Fotino M. Immunogenetic and clinical findings in idiopathic pulmonary fibrosis: association with the B-cell alloantigen HLA-DR2. Am Rev Respir Dis . 1983; 127 618-622
- 56 Musk A W, Zilko P J, Manners P. Genetic studies in familial fibrosing alveolitis: possible linkage with immunoglobulin allotypes (Gm). Chest . 1986; 89 206-210
- 57 Whyte M, Hubbard R, Meliconi R. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med . 2000; 162 755-758
- 58 Wilson A G, Symons J A, McDowell T L. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A . 1997; 94 3195-3199
- 59 Danis V A, Millington M, Hyland V J. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol . 1995; 99 303-310
- 60 Pantelidis P, Fanning G C, Wells A U. Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med . 2001; 163 1432-1436
- 61 Raghu G, Hert R. Interstitial lung disease: genetic predisposition and inherited interstitial lung disease. Sem Respir Critical Care Med . 1993; 14 323-332
- 62 Sandoz E. Uber zwei Falle von fotaler Bronchektasie. Beitr Pathol Anat . 1907; 41 496-517
- 63 Marshall R P, Puddicombe A, Cookson W O. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax . 2000; 55 143-146
- 64 Barzo P. Familial idiopathic fibrosing alveolitis. Eur J Respir Dis . 1985; 66 350-352
- 65 Hwang H C, Raghu G, Schmidt R. Pathologic features of familial versus sporadic cases of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med . 1997; 155 A323
- 66 Raghu G. Genetic study of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med . 1996; 153 A689
- 67 Uchiyama E A. Unexpectedly high incidence of idiopathic pulmonary fibrosis among siblings of patients with IPF in Japan (Abstract). Am J Respir Crit Care Med . 1995; 153 A405
- 68 Johnston I D, Prescott R J, Chalmers J C. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax . 1997; 52 38-44
- 69 Bitterman P B, Rennard S I, Keogh B A. Familial idiopathic pulmonary fibrosis: evidence of lung inflammation in unaffected family members. N Engl J Med . 1986; 314 1343-1347
- 70 Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood . 1959; 14 162-169
- 71 Gahl W A, Brantly M, Kaiser-Kupfer M I. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med . 1998; 338 1258-1264
- 72 Harmon K R, Witkop C J, White J G. Pathogenesis of pulmonary fibrosis: platelet-derived growth factor precedes structural alterations in the Hermansky-Pudlak syndrome. J Lab Clin Med . 1994; 123 617-627
- 73 Garay S M, Gardella J E, Fazzini E P. Hermansky-Pudlak syndrome: pulmonary manifestations of a ceroid storage disorder. Am J Med . 1979; 66 737-747
- 74 Schinella R A, Greco M A, Cobert B L. Hermansky-Pudlak syndrome with granulomatous colitis. Ann Intern Med . 1980; 92 20-23
- 75 Witkop C J, Nunez Babcock M, Rao G H. Albinism and Hermansky-Pudlak syndrome in Puerto Rico. Bol Asoc Med P R . 1990; 82 333-339
- 76 Witkop C J, Quevedo W C, Fitzpatrick T B. Albinism. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic basis of inherited disease New York: McGraw-Hill 1989
- 77 Oh J, Bailin T, Fukai K. Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet . 1996; 14 300-306
- 78 Oetting W S, King R A. Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat . 1999; 13 99-115
- 79 Brantly M, Avila N A, Shotelersuk V. Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest . 2000; 117 129-136
- 80 Davies B H, Tuddenham E G. Familial pulmonary fibrosis associated with oculocutaneous albinism and platelet function defect: a new syndrome. Q J Med . 1976; 45 219-232
- 81 Leitman B S, Balthazar E J, Garay S M. The Hermansky-Pudlak syndrome: radiographic features. Can Assoc Radiol J . 1986; 37 42-45
- 82 Hoyle G W, Li J, Finkelstein J B. Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am J Pathol . 1999; 154 1763-1775
- 83 Minai O A, Sullivan E J, Stoller J K. Pulmonary involvement in Niemann-Pick disease: case report and literature review. Respir Med . 2000; 94 1241-1251
- 84 Kolodny E H. Niemann-Pick disease. Curr Opin Hematol . 2000; 7 48-52
- 85 Lachman R, Crocker A, Schulman J. Radiological findings in Niemann-Pick disease. Radiology . 1973; 108 659-664
- 86 Schofer O, Mischo B, Puschel W. Early-lethal pulmonary form of Niemann-Pick type C disease belonging to a second, rare genetic complementation group. Eur J Pediatr . 1998; 157 45-49
- 87 Skikne M I, Prinsloo I, Webster I. Electron microscopy of lung in Niemann-Pick disease. J Pathol . 1972; 106 119-122
- 88 Lever A M, Ryder J B. Cor pulmonale in an adult secondary to Niemann-Pick disease. Thorax . 1983; 38 873-874
- 89 Charrow J, Esplin J A, Gribble T J. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med . 1998; 158 1754-1760
- 90 Charrow J, Andersson H C, Kaplan P. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med . 2000; 160 2835-2843
- 91 Schneider E L, Epstein C J, Kaback M J. Severe pulmonary involvement in adult Gaucher's disease: report of three cases and review of the literature. Am J Med . 1977; 63 475-480
- 92 Dawson A, Elias D J, Rubenson D. Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med . 1996; 125 901-904
- 93 Banjar H. Pulmonary involvement of Gaucher's disease in children: a common presentation in Saudi Arabia. Ann Trop Paediatr . 1998; 18 55-59
- 94 Castro M, Shepherd C W, Gomez M R. Pulmonary tuberous sclerosis. Chest . 1995; 107 189-195
- 95 Chan J K, Tsang W Y, Pau M Y. Lymphangiomyomatosis and angiomyolipoma: closely related entities characterized by hamartomatous proliferation of HMB-45-positive smooth muscle. Histopathology . 1993; 22 445-455
- 96 Carbonara C, Longa L, Grosso E. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer . 1996; 15 18-25
- 97 Carbonara C, Longa L, Grosso E. 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Hum Mol Genet . 1994; 3 1829-1832
- 98 Smolarek T A, Wessner L L, McCormack F X. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet . 1998; 62 810-815
- 99 Astrinidis A, Khare L, Carsillo T. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet . 2000; 37 55-57
- 100 Carsillo T, Astrinidis A, Henske E P. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A . 2000; 97 6085-6090
- 101 Mulvihill J J, Parry D M, Sherman J L. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis): an update. Ann Intern Med . 1990; 113 39-52
- 102 Li Y, O'Connell P, Breidenbach H H. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics . 1995; 25 9-18
- 103 Kloos R T, Rufini V, Gross M D. Bone scans in neurofibromatosis: neurofibroma, plexiform neuroma and neurofibrosarcoma. J Nucl Med . 1996; 37 1778-1783
- 104 Evans D G, Huson S M, Donnai D. A clinical study of type 2 neurofibromatosis. Q J Med . 1992; 84 603-618
- 105 De Vitis R L, Tedde A, Vitelli F. Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin. Hum Genet . 1996; 97 638-641
- 106 Colman S D, Rasmussen S A, Ho V T. Somatic mosaicism in a patient with neurofibromatosis type 1. Am J Hum Genet . 1996; 58 484-490
- 107 Davis S A, Kaplan R L. Neurofibromatosis and interstitial lung disease. Arch Dermatol . 1978; 114 1368-1369
- 108 Webb W R, Goodman P C. Fibrosing alveolitis in patients with neurofibromatosis. Radiology . 1977; 122 289-293
- 109 Meyer F J, Teschler H, Schnabel R. Bronchoalveolar lavage cytology in pulmonary fibrosis associated with neurofibromatosis. Respir Med . 1996; 90 365-367
- 110 Massaro D, Katz S. Fibrosing alveolitis: its occurrence, roentgenographic, and pathologic features in von Recklinghausen's neurofibromatosis. Am Rev Respir Dis . 1966; 93 934-942
- 111 Atit R P, Crowe M J, Greenhalgh D G. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol . 1999; 112 835-842
- 112 Foley Jr P T, Harrison H C, Arnaud C D. Familial benign hypercalcemia. J Pediatr . 1972; 81 1060-1067
- 113 Marx S J, Attie M F, Levine M A. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore) . 1981; 60 397-412
- 114 Brown E M. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol Metab Clin North Am . 2000; 29 503-522
- 115 Demedts M, Auwerx J, Goddeeris P. The inherited association of interstitial lung disease, hypocalciuric hypercalcemia, and defective granulocyte function. Am Rev Respir Dis . 1985; 131 470-475
- 116 Auwerx J, Boogaerts M, Ceuppens J L. Defective host defence mechanisms in a family with hypocalciuric hypercalcaemia and coexisting interstitial lung disease. Clin Exp Immunol . 1985; 62 57-64